<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03960710</url>
  </required_header>
  <id_info>
    <org_study_id>ASEPOL</org_study_id>
    <nct_id>NCT03960710</nct_id>
  </id_info>
  <brief_title>Automatic Segmentation of Polycystic Liver</brief_title>
  <acronym>ASEPOL</acronym>
  <official_title>Automatic Segmentation by a Convolutional Neural Network (Artificial Intelligence - Deep Learning) of Polycystic Livers, as a Model of Multi-lesional Dysmorphic Livers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessing the volume of the liver before surgery, predicting the volume of liver remaining&#xD;
      after surgery, detecting primary or secondary lesions in the liver parenchyma are common&#xD;
      applications that require optimal detection of liver contours, and therefore liver&#xD;
      segmentation.&#xD;
&#xD;
      Several manual and laborious, semi-automatic and even automatic techniques exist.&#xD;
&#xD;
      However, severe pathology deforming the contours of the liver (multi-metastatic livers...),&#xD;
      the hepatic environment of similar density to the liver or lesions, the CT examination&#xD;
      technique are all variables that make it difficult to detect the contours. Current&#xD;
      techniques, even automatic ones, are limited in this type of case (not rare) and most often&#xD;
      require readjustments that make automatisation lose its value.&#xD;
&#xD;
      All these criteria of segmentation difficulties are gathered in the livers of hepatorenal&#xD;
      polycystosis, which therefore constitute an adapted study model for the development of an&#xD;
      automatic segmentation tool.&#xD;
&#xD;
      To obtain an automatic segmentation of any lesional liver, by exceeding the criteria of&#xD;
      difficulty considered, investigators have developed a convolutional neural network&#xD;
      (artificial intelligence - deep learning) useful for clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 1, 2019</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Test of automatic segmentation by the convolutional neural network on these group and collection of data set</measure>
    <time_frame>At 4 months after randomization</time_frame>
    <description>Development of an automatic segmentation tool for highly dysmorphic polycystic livers as a prerequisite for segmentation of any type of multi-lesional livers that are difficult to segment, in order to facilitate lesion detection and volume measurement in clinical practice.&#xD;
Randomisation of the patient into two data groups, one for training the other for Validating the convolutional neural network (artificial intelligence)&#xD;
Manual segmentation of polycystic livers of the 1st training group and deep learning of convolutional neural network&#xD;
Manual segmentation of polycystic livers of 2nd validation group&#xD;
Test of automatic segmentation by the convolutional neural network on these group and collection of data set</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Polycystic Liver Disease</condition>
  <condition>Polycystic Hepatorenal Disease</condition>
  <condition>Liver Injury</condition>
  <arm_group>
    <arm_group_label>Neuronal network Training group</arm_group_label>
    <description>The following radiological variables, related to each CT examinations, will be collected for each patient:&#xD;
Injection modalities (without injection, injected)&#xD;
Major hepatectomy surgery&#xD;
Importance of hepatic dysmorphia&#xD;
Presence of intraperitoneal fluid effusion&#xD;
Presence of renal polycystosis (especially on the right side).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Neuronal network Validation group</arm_group_label>
    <description>The following radiological variables, related to each CT examinations, will be collected for each patient:&#xD;
Injection modalities (without injection, injected)&#xD;
Major hepatectomy surgery&#xD;
Importance of hepatic dysmorphia&#xD;
Presence of intraperitoneal fluid effusion&#xD;
Presence of renal polycystosis (especially on the right side).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Anonymized CT examinations</intervention_name>
    <description>The anonymized CT examinations will be reviewed in Lyon, in the imaging department of Edouard Herriot Hospital, by an expert radiologist and an intern from the Lyon hospitals.</description>
    <arm_group_label>Neuronal network Training group</arm_group_label>
    <arm_group_label>Neuronal network Validation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Training (1)</intervention_name>
    <description>An initial training phase of the artificial intelligence network will be carried out :&#xD;
- Segmentation of the livers of a first part of the CT examination, by an intern of the Lyon hospitals</description>
    <arm_group_label>Neuronal network Training group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Training (2)</intervention_name>
    <description>An initial training phase of the artificial intelligence network will be carried out :&#xD;
- Use of computer data to drive the artificial intelligence network.</description>
    <arm_group_label>Neuronal network Training group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Validation (1)</intervention_name>
    <description>A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :&#xD;
- Carried out by an intern at the Lyon hospitals</description>
    <arm_group_label>Neuronal network Validation group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Validation (2)</intervention_name>
    <description>A validation phase of the artificial intelligence tool will be carried out with segmentation of the livers of the second part of the CT examinations :&#xD;
- Carried out by the neural network</description>
    <arm_group_label>Neuronal network Validation group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with hepato-renal polycystosis, with or without surgery&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 years old&#xD;
&#xD;
          -  Patients with hepato-renal polycystosis, with or without surgery&#xD;
&#xD;
          -  Patients with at least one abdominal-pelvic CT scan without injection or with&#xD;
             injection between January 1, 2016 and August 2018&#xD;
&#xD;
          -  Patients with good quality and available images&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with no CT scan images available&#xD;
&#xD;
          -  Patients with bad quality of CT scan images&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bénédicte CAYOT</last_name>
    <phone>472110400</phone>
    <phone_ext>+33</phone_ext>
    <email>benedicte.cayot@chu-lyon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Pierre-Jean VALETTE, MD, Prof.</last_name>
    <phone>472117544</phone>
    <phone_ext>+33</phone_ext>
    <email>pierre-jean.valette@chu-lyon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service de radiologie - Pavillon B - Cellule Recherche imagerie, Hôpital Edouard Herriot (HCL)</name>
      <address>
        <city>Lyon</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bénédicte CAYOT</last_name>
      <phone>472110400</phone>
      <phone_ext>+33</phone_ext>
      <email>benedicte.cayot@chu-lyon.fr</email>
    </contact>
    <contact_backup>
      <last_name>Pierre-Jean VALETTE, MD, Prof.</last_name>
      <phone>472117544</phone>
      <phone_ext>+33</phone_ext>
      <email>pierre-jean.valette@chu-lyon.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Pierre-Jean VALETTE, MD, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 21, 2019</study_first_submitted>
  <study_first_submitted_qc>May 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2019</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

